Everest Medicines reaches its first peak in China with Trodelvy nod; Cyclerion touts data in small study
While struggling at home to prove significant difference in overall survival compared to standard of care, Gilead’s Trodelvy is headed to China through partner Everest Medicines.
The country has approved the drug for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer. Patients must have taken two or more prior systemic therapies. CEO Kerry Blanchard called the approval a “significant milestone” for Everest as it marks the biotech’s first nod in its home country.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.